Clin2
NCT07469293Possibly a fitNot yet recruiting

Study of artery-injected tenecteplase for stroke with medium vessel blockage

Acute Ischemic Stroke

Treatments studied

Part of Brain & nervous system, Heart & circulation clinical trials.

This trial tests a clot-busting drug called tenecteplase, given directly into the blocked artery, for people who have had a stroke caused by a medium-sized brain vessel blockage within the last 24 hours. It aims to see if this treatment is safe and effective in improving recovery.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
488 people
Ages
18 years to 100 years
Study type
Interventional

Who can take part

  • You are 18 years or older
  • You had a stroke from a medium-sized brain vessel blockage, confirmed by imaging, and treatment starts within 24 hours of symptoms beginning
  • Your stroke symptoms are at least moderately severe (NIHSS score of 5 or higher)
  • A CT scan shows the stroke area is not too large
  • You were able to do your daily activities without help before the stroke (mRS score 0 or 1)
  • You have not already received clot-dissolving medicine through an IV for this stroke

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07302854Recruiting· Phase 2/Phase 3
Clot-busting medicine for medium vessel strokes

This trial tests a new clot-busting medicine called tenecteplase, given directly into the blood vessel in the brain, to treat strokes caused by a blockage in a medium-sized artery. The goal is to see if it can help restore blood flow and reduce disability, especially for patients who can be treated within 24 hours of stroke onset.

Wuhan, Hubei
NCT07137832Recruiting· Phase 3
Testing clot-busting drug during stroke treatment for medium vessel blockages

This trial tests whether giving a clot-dissolving medication directly into the brain's blood vessels during a standard procedure (mechanical thrombectomy) can improve outcomes for people with a stroke caused by a blockage in a medium-sized artery. It may be an option for patients who arrive at the hospital within 24 hours of symptom onset and have enough salvageable brain tissue.

Guangzhou, Guangdong
NCT06781385Enrolling by invitation· Phase 2
Tenecteplase after clot removal for severe stroke

This trial tests if giving a clot-busting drug (tenecteplase) directly into the brain artery after a successful clot-removal procedure can improve outcomes for people with a major stroke. It is for patients who had a large vessel blockage and received endovascular thrombectomy within 24 hours of symptoms starting.

Charlotte, North Carolina
NCT06559436Recruiting
Extending window for clot-busting drug in medium vessel stroke

This trial tests a clot-dissolving drug called tenecteplase given 4.5 to 24 hours after a stroke caused by a blockage in a medium-sized brain artery. It aims to see if waiting longer than usual still helps reduce disability.

Hefei, Anhui
NCT07168278Not yet recruiting· Phase 3
Tenecteplase vs standard care for large vessel stroke 4.5-24 hours

This trial tests if a clot-busting drug called tenecteplase can improve outcomes for people with a large vessel stroke when treatment starts 4.5 to 24 hours after symptoms began, and when a mechanical clot removal procedure (EVT) is not available. You would receive tenecteplase or standard medical care to see which works better.

Hefei, Anhui
NCT07361302Recruiting· Phase 3
Tenecteplase for stroke after 4.5 hours

This trial tests a clot-dissolving medicine called tenecteplase for people who had a stroke more than 4.5 hours ago. It may help you recover if given later than usual.

Buenos Aires

Hear when a new Acute Ischemic Stroke trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.